MAZE
NASDAQMaze Therapeutics Inc.
Maze Therapeutics Inc. (MAZE) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for MAZE, including 4 SEC filings, 2 insider trades and 1 analyst rating. The most recent was published Nov 9, 2026.
MAZE rankings
Price$34.29+6.59 (+23.79%)
2026-08-132026-11-13
Financial highlights
Full financials- Net income, TTM
- -$151.47M
- Free cash flow, TTM
- -$115.26M
- Cash
- $154.16M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks59+14%
2026-05-172026-11-08
Mix3090d
- Insider15(50%)
- SEC Filings9(30%)
- Other3(10%)
- Analyst2(7%)
- Earnings1(3%)
Activity · 52 weeks11262 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Maze Therapeutics Inc.10-Q - Maze Therapeutics, Inc. (0001842295) (Filer)
- SECMaze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- PRMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsEnrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477 million in cash, cash equivalents and marketable securities as of September 30, 2026 supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the
- INSIDERChief Executive Officer Coloma Jason V sold $1,043,766 worth of shares (34,501 units at $30.25) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- PRMaze Therapeutics to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences: 3rd Annual Guggenheim Healthcare Innovation Conference; fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. ET2026 Jefferies Global Healthcare Conference in London; presentation on Tuesday, November 17, 2026, at 10:30 a.m. ET / 3:30 p.m. GMT9th Annual Evercore Healthcare Conference; fireside chat on Tuesd
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- INSIDERCSBO Dandekar Atul sold $240,532 worth of shares (7,500 units at $32.07) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Maze Therapeutics with a new price targetCanaccord Genuity initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $75.00
- SECSEC Form 8-K filed by Maze Therapeutics Inc.8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- PRMaze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held Octobe
- INSIDERChief Executive Officer Coloma Jason V sold $932,260 worth of shares (34,501 units at $27.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERPresident, R&D & CMO Bernstein Harold exercised 16,141 shares at a strike of $10.42 and sold $434,743 worth of shares (16,141 units at $26.93) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERCSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $202,921 worth of shares (7,500 units at $27.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- ANALYSTCitigroup initiated coverage on Maze Therapeutics with a new price targetCitigroup initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $50.00
- INSIDERPresident, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERGC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERChief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERCSBO Dandekar Atul converted options into 12,500 shares, increasing direct ownership by 48% to 38,750 units (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERPresident, R&D & CMO Bernstein Harold exercised 36,141 shares at a strike of $4.65 and sold $425,512 worth of shares (16,141 units at $26.36) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- PRMaze Therapeutics to Participate in Three Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ETCiti 2026 Biopharma Back to School Summit; fireside chat on Thursday, September 10, 2026, at 2:20 p.m. ETH.C. Wainwright 28th Annual Global Investment Conference; fireside chat on Tuesday, September 15, 2026, at 9:00 a.m. ET Live webcasts of the eve
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- INSIDERCSBO Dandekar Atul sold $206,824 worth of shares (7,500 units at $27.58) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $10.42 (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
MAZE FAQ
9 questionsWhat is the latest news on MAZE?
In the last 30 days Quantisnow tracked 9 wire items for MAZE: 4 SEC filings, 2 insider trades, 1 analyst rating and 1 press release or news item. The most recent was published on November 9, 2026.Is MAZE profitable?
No. Maze Therapeutics Inc. reported a net loss of $151.47M for the twelve months ended Sep 30, 2026.How much cash and debt does MAZE have?
Maze Therapeutics Inc. reported $154.16M in cash and cash equivalents and $39.12M of debt on its most recent balance sheet in SEC filings.Where does MAZE stock trade?
Maze Therapeutics Inc. (MAZE) is listed on NASDAQ.What sector and industry is MAZE in?
Maze Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Maze Therapeutics Inc. go public?
Maze Therapeutics Inc. (MAZE) completed its IPO in 2025.What are analysts saying about MAZE?
Maze Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $75.00 price target on 2026-10-19. Recent price targets range from $30.00 to $97.00.What companies are similar to MAZE?
Notable peers in the same industry include MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare MAZE side-by-side with any of them on Quantisnow.How can I track MAZE on Quantisnow?
Quantisnow aggregates Maze Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MAZE to receive live email and push alerts on every new disclosure.